Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus

Clinical and Epidemiological Characteristics and Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus Under Routine Clinical Practice

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03437109

Acronym

DESTINY

Enrollment

554

Registered

2018-02-19

Start date

2017-12-06

Completion date

2019-02-01

Last updated

2019-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T2DM (Type 2 Diabetes Mellitus), Hypogonadism

Brief summary

The purpose of the study is to get data of prevalence of testosterone deficiency in patient with T2DM in Russian Federation

Detailed description

Clinical and Epidemiological Characteristics and Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus Under Routine Clinical Practice (DESTINY)

Interventions

DIAGNOSTIC_TESTLaboratory tests

Testosterone HSBG Hb1Ac LH

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

45 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Male 45-60 years old * Diagnosis of T2DM according to approved standards * Signed Informed Consent Form

Exclusion criteria

* Prepubertal hypogonadism of any genesis; * Sexual and developmental disorders; * Absence of at least one of the testicles; * Cryptorchidism, including in the anamnesis; * Injuries and / or surgical interventions on the genitals with loss of at least one of the testicles; * Established diagnosis of panhypopituitarism in accordance with current recommendations / standards; * Androgen therapy, administered at the time of the study or in the anamnesis; * Admission of anabolic steroids; * Alcoholism or drug addiction; * Insolvency.

Design outcomes

Primary

Measure	Time frame	Description
The prevalence of hypogonadism in patients with T2DM	2017-2018	The prevalence of hypogonadism in patients with T2DM

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026